Onyx Rises as Liver Cancer Drug Outperforms Pfizer’s (Update2)
April 23 (Bloomberg) — Onyx Pharmaceuticals Inc. increased the most in nine months after its Nexavar treatment for advanced liver cancer outperformed a potential competitor from Pfizer Inc.

Read more on Bloomberg